HeartSciences (HSCS) Competitors

$1.93 -0.01 (-0.52%)

As of 05/8/2026 04:00 PM Eastern

HSCS vs. ICCM, RVP, ICU, OSRH, and POAI

Should you be buying HeartSciences stock or one of its competitors? The main competitors of HeartSciences include IceCure Medical (ICCM), Retractable Technologies (RVP), SeaStar Medical (ICU), OSR (OSRH), and Predictive Oncology (POAI). These companies are all part of the "medical equipment" industry.

How does HeartSciences compare to IceCure Medical?

IceCure Medical (NASDAQ:ICCM) and HeartSciences (NASDAQ:HSCS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

In the previous week, IceCure Medical had 1 more articles in the media than HeartSciences. MarketBeat recorded 4 mentions for IceCure Medical and 3 mentions for HeartSciences. HeartSciences' average media sentiment score of 0.33 beat IceCure Medical's score of 0.00 indicating that HeartSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IceCure Medical	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
HeartSciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

IceCure Medical has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Comparatively, HeartSciences has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500.

IceCure Medical presently has a consensus target price of $2.64, indicating a potential upside of 997.92%. HeartSciences has a consensus target price of $8.00, indicating a potential upside of 314.51%. Given IceCure Medical's stronger consensus rating and higher probable upside, equities analysts plainly believe IceCure Medical is more favorable than HeartSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

HeartSciences has lower revenue, but higher earnings than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.38M	5.76	-$15.06M	-$0.24	N/A
HeartSciences	N/A	N/A	-$8.77M	-$4.94	N/A

0.6% of IceCure Medical shares are owned by institutional investors. Comparatively, 17.2% of HeartSciences shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by company insiders. Comparatively, 4.9% of HeartSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

HeartSciences has a net margin of 0.00% compared to IceCure Medical's net margin of -445.61%. IceCure Medical's return on equity of -221.04% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-445.61%	-221.04%	-118.89%
HeartSciences	N/A	-333.50%	-140.18%

Summary

IceCure Medical beats HeartSciences on 8 of the 15 factors compared between the two stocks.

How does HeartSciences compare to Retractable Technologies?

Retractable Technologies (NYSE:RVP) and HeartSciences (NASDAQ:HSCS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

HeartSciences has a net margin of 0.00% compared to Retractable Technologies' net margin of -41.11%. Retractable Technologies' return on equity of -17.15% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Retractable Technologies	-41.11%	-17.15%	-9.33%
HeartSciences	N/A	-333.50%	-140.18%

Retractable Technologies has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Comparatively, HeartSciences has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500.

HeartSciences has a consensus price target of $8.00, indicating a potential upside of 314.51%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts clearly believe HeartSciences is more favorable than Retractable Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Retractable Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Retractable Technologies has higher revenue and earnings than HeartSciences. Retractable Technologies is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Retractable Technologies	$38.27M	0.55	-$7.01M	-$0.42	N/A
HeartSciences	N/A	N/A	-$8.77M	-$4.94	N/A

7.6% of Retractable Technologies shares are owned by institutional investors. Comparatively, 17.2% of HeartSciences shares are owned by institutional investors. 59.5% of Retractable Technologies shares are owned by company insiders. Comparatively, 4.9% of HeartSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, HeartSciences had 2 more articles in the media than Retractable Technologies. MarketBeat recorded 3 mentions for HeartSciences and 1 mentions for Retractable Technologies. HeartSciences' average media sentiment score of 0.33 beat Retractable Technologies' score of 0.00 indicating that HeartSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Retractable Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
HeartSciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

HeartSciences beats Retractable Technologies on 9 of the 15 factors compared between the two stocks.

How does HeartSciences compare to SeaStar Medical?

HeartSciences (NASDAQ:HSCS) and SeaStar Medical (NASDAQ:ICU) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

HeartSciences has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500. Comparatively, SeaStar Medical has a beta of -1.04, suggesting that its stock price is 204% less volatile than the S&P 500.

HeartSciences has a net margin of 0.00% compared to SeaStar Medical's net margin of -984.60%. SeaStar Medical's return on equity of -188.47% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartSciences	N/A	-333.50%	-140.18%
SeaStar Medical	-984.60%	-188.47%	-106.42%

HeartSciences has higher earnings, but lower revenue than SeaStar Medical. SeaStar Medical is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartSciences	N/A	N/A	-$8.77M	-$4.94	N/A
SeaStar Medical	$1.23M	14.60	-$12.15M	-$8.30	N/A

HeartSciences currently has a consensus target price of $8.00, suggesting a potential upside of 314.51%. SeaStar Medical has a consensus target price of $6.00, suggesting a potential upside of 33.63%. Given HeartSciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe HeartSciences is more favorable than SeaStar Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SeaStar Medical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

17.2% of HeartSciences shares are owned by institutional investors. Comparatively, 1.7% of SeaStar Medical shares are owned by institutional investors. 4.9% of HeartSciences shares are owned by company insiders. Comparatively, 0.7% of SeaStar Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, HeartSciences had 1 more articles in the media than SeaStar Medical. MarketBeat recorded 3 mentions for HeartSciences and 2 mentions for SeaStar Medical. SeaStar Medical's average media sentiment score of 0.98 beat HeartSciences' score of 0.33 indicating that SeaStar Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HeartSciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SeaStar Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

HeartSciences beats SeaStar Medical on 11 of the 15 factors compared between the two stocks.

How does HeartSciences compare to OSR?

OSR (NASDAQ:OSRH) and HeartSciences (NASDAQ:HSCS) are both small-cap medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

HeartSciences has a net margin of 0.00% compared to OSR's net margin of -619.82%. OSR's return on equity of -13.53% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OSR	-619.82%	-13.53%	-10.17%
HeartSciences	N/A	-333.50%	-140.18%

HeartSciences has lower revenue, but higher earnings than OSR. OSR is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OSR	$2.91M	6.49	-$27.06M	-$1.28	N/A
HeartSciences	N/A	N/A	-$8.77M	-$4.94	N/A

OSR has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, HeartSciences has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500.

55.3% of OSR shares are held by institutional investors. Comparatively, 17.2% of HeartSciences shares are held by institutional investors. 60.6% of OSR shares are held by insiders. Comparatively, 4.9% of HeartSciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, HeartSciences had 2 more articles in the media than OSR. MarketBeat recorded 3 mentions for HeartSciences and 1 mentions for OSR. HeartSciences' average media sentiment score of 0.33 beat OSR's score of 0.00 indicating that HeartSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OSR	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
HeartSciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

HeartSciences has a consensus target price of $8.00, suggesting a potential upside of 314.51%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts clearly believe HeartSciences is more favorable than OSR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

HeartSciences beats OSR on 9 of the 15 factors compared between the two stocks.

How does HeartSciences compare to Predictive Oncology?

Predictive Oncology (NASDAQ:POAI) and HeartSciences (NASDAQ:HSCS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

HeartSciences has a net margin of 0.00% compared to Predictive Oncology's net margin of -5,065.23%. HeartSciences' return on equity of -333.50% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-5,065.23%	-732.73%	-235.55%
HeartSciences	N/A	-333.50%	-140.18%

In the previous week, HeartSciences had 2 more articles in the media than Predictive Oncology. MarketBeat recorded 3 mentions for HeartSciences and 1 mentions for Predictive Oncology. HeartSciences' average media sentiment score of 0.33 beat Predictive Oncology's score of 0.00 indicating that HeartSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Predictive Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
HeartSciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

HeartSciences has lower revenue, but higher earnings than Predictive Oncology. Predictive Oncology is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.66M	12.17	-$12.66M	-$13.50	N/A
HeartSciences	N/A	N/A	-$8.77M	-$4.94	N/A

HeartSciences has a consensus target price of $8.00, suggesting a potential upside of 314.51%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts plainly believe HeartSciences is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Predictive Oncology has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500. Comparatively, HeartSciences has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500.

9.0% of Predictive Oncology shares are held by institutional investors. Comparatively, 17.2% of HeartSciences shares are held by institutional investors. 1.2% of Predictive Oncology shares are held by insiders. Comparatively, 4.9% of HeartSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

HeartSciences beats Predictive Oncology on 14 of the 15 factors compared between the two stocks.

Get HeartSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HSCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HSCS vs. The Competition

Export

Metric	HeartSciences	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.18M	$1.49B	$6.25B	$12.12B
Dividend Yield	N/A	N/A	2.78%	5.20%
P/E Ratio	-0.39	67.17	20.87	25.39
Price / Sales	N/A	6.03	534.03	75.96
Price / Cash	N/A	23.95	43.29	53.47
Price / Book	10.72	4.92	9.98	6.81
Net Income	-$8.77M	-$54.60M	$3.54B	$333.04M
7 Day Performance	-3.02%	-1.32%	3.50%	3.17%
1 Month Performance	-10.65%	10.50%	4.17%	7.14%
1 Year Performance	-43.73%	2.03%	41.86%	41.22%

HeartSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HSCS HeartSciences	2.7706 of 5 stars	$1.93 -0.5%	$8.00 +314.5%	N/A	$6.18M	N/A	N/A	10	Gap Up
ICCM IceCure Medical	2.1756 of 5 stars	$0.27 -6.6%	$2.64 +890.6%	N/A	$21.59M	$3.38M	N/A	60	News Coverage Upcoming Earnings
RVP Retractable Technologies	N/A	$0.69 -4.3%	N/A	N/A	$20.75M	$38.27M	N/A	240
ICU SeaStar Medical	2.1669 of 5 stars	$4.87 +10.2%	$6.00 +23.2%	N/A	$19.48M	$1.23M	N/A	2	Upcoming Earnings
OSRH OSR	0.9414 of 5 stars	$0.58 +12.7%	N/A	N/A	$19.34M	$2.91M	N/A	N/A	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HSCS) was last updated on 5/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HeartSciences (HSCS) Competitors

HSCS vs. ICCM, RVP, ICU, OSRH, and POAI

How does HeartSciences compare to IceCure Medical?

Summary

How does HeartSciences compare to Retractable Technologies?

Summary

How does HeartSciences compare to SeaStar Medical?

Summary

How does HeartSciences compare to OSR?

Summary

How does HeartSciences compare to Predictive Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSCS vs. The Competition

HeartSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HeartSciences (HSCS) Competitors

HSCS vs. ICCM, RVP, ICU, OSRH, and POAI

How does HeartSciences compare to IceCure Medical?

Does the media favor ICCM or HSCS?

Which has more volatility & risk, ICCM or HSCS?

Do analysts prefer ICCM or HSCS?

Which has better earnings and valuation, ICCM or HSCS?

Do institutionals & insiders believe in ICCM or HSCS?

Is ICCM or HSCS more profitable?

Summary

How does HeartSciences compare to Retractable Technologies?

Is RVP or HSCS more profitable?

Which has more volatility & risk, RVP or HSCS?

Do analysts prefer RVP or HSCS?

Which has stronger valuation & earnings, RVP or HSCS?

Do insiders and institutionals have more ownership in RVP or HSCS?

Does the media prefer RVP or HSCS?

Summary

How does HeartSciences compare to SeaStar Medical?

Which has more risk and volatility, HSCS or ICU?

Is HSCS or ICU more profitable?

Which has better valuation & earnings, HSCS or ICU?

Do analysts prefer HSCS or ICU?

Do insiders and institutionals have more ownership in HSCS or ICU?

Does the media favor HSCS or ICU?

Summary

How does HeartSciences compare to OSR?

Is OSRH or HSCS more profitable?

Which has higher valuation and earnings, OSRH or HSCS?

Which has more volatility & risk, OSRH or HSCS?

Do institutionals and insiders believe in OSRH or HSCS?

Does the media refer more to OSRH or HSCS?

Do analysts prefer OSRH or HSCS?

Summary

How does HeartSciences compare to Predictive Oncology?

Is POAI or HSCS more profitable?

Does the media favor POAI or HSCS?

Which has stronger earnings and valuation, POAI or HSCS?

Do analysts prefer POAI or HSCS?

Which has more risk and volatility, POAI or HSCS?

Do insiders and institutionals hold more shares of POAI or HSCS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSCS vs. The Competition

HeartSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools